Lead Sponsor

Ottawa Hospital Research Institute

Collaborators

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
the Association médicale universitaire de l'Hôpital Montfort (AMUHM)
Canadian Hematology Society

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Male or female subjects aged 18 years or older,
•2. Confirmed diagnosis of PV, JAK2ET or JAK2 pre-fibrotic MF, per local clinical definitions
•3. Able and willing to comply with study procedures and follow-up examinations contained within the written consent form

•1. Known allergy to apixaban or aspirin,
•2. Another need for anticoagulation or specific anti-platelet therapy,
•3. Contraindication to thromboprophylaxis (which would specifically include but not be limited to platelets less than 50x10\^9/L and acquired Von Willebrand disease),
•4. Current pregnancy or breast-feeding,
•5. Renal dysfunction (Creatine Clearance \<25 mL/min),
•6. Known liver disease
•7. Currently on any medication with a known interaction to apixaban
•8. Unwilling to use an effective means of contraception for women of childbearing potential
•9. Overtly fibrotic myelofibrosis
•10. Myelodysplastic/myeloproliferative neoplasms

Related studies

NCT06859424 · AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), and more

NCT06541249 · Polycythemia Vera (PV), Essential Thrombocythemia (ET), and more

NCT02577926 · Polycythemia Vera (PV), Essential Thrombocythemia (ET)

NCT06798805 · Essential Thrombocythemia (ET), Myelofibrosis (MF), and more

NCT05123326 · Hepatic Vein Thromboses, Hepatic Venous Outflow Obstruction, and more

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients